Insight
60% of US women to have cardiovascular disease by 2050 – study

Nearly six in 10 US women are projected to have cardiovascular disease by 2050, driven largely by rising rates of high blood pressure, according to a new American Heart Association scientific statement.
Cardiovascular disease refers to conditions affecting the heart and blood vessels, including heart disease, heart failure, atrial fibrillation, which is an irregular heartbeat, and stroke.
The projected increase over the next 25 years is linked to growing rates of high blood pressure, diabetes and obesity.
Karen E. Joynt Maddox is professor of medicine and public health at Washington University School of Medicine in St. Louis and chair of the statement writing group.
She said: “One in every three women will die from cardiovascular disease, maybe it’s your grandmother, or your mother or your daughter.
“Additionally, more than 62 million women in the US are living with some type of cardiovascular disease and that comes with a price tag of at least US$200 billion, annually.
“Our estimates indicate that if we stay on the current path, these numbers will grow substantially over the next 25 to 30 years.”
More than 62m women in the US are currently living with some form of cardiovascular disease, at an estimated annual cost of at least US$200bn.
The statement found that by 2050 nearly 60 per cent of women are expected to have high blood pressure, up from about five in 10 previously reported for 2020.
More than 25 per cent are projected to have diabetes, compared with about 15 per cent now, and more than 60 per cent are expected to have obesity, up from about 44 per cent.
The trend is also projected to affect younger women and girls.
By 2050, nearly one in three women aged 22 to 44 are expected to have some form of cardiovascular disease, compared with less than one in four currently.
Diabetes in this age group is projected to rise from 6 per cent to nearly 16 per cent.
More than a third of women aged 22 to 44 are expected to have high blood pressure, and more than one in six are projected to have obesity.
Among girls aged two to 19, close to 32 per cent are projected to have obesity, an increase of more than 12 per cent.
Rates are expected to be higher among Black girls, with around 40 per cent projected to have obesity by 2050.
Among women of colour, some of the largest increases are forecast.
High blood pressure is projected to rise most among Hispanic women, by more than 15 per cent. Obesity is expected to increase most among Asian women, by nearly 26 per cent.
Rates of cardiovascular risk factors are projected to remain highest among Black women, with more than 70 per cent expected to have high blood pressure, more than 71 per cent to have obesity and nearly 28 per cent to have diabetes.
Stacey E. Rosen is volunteer president of the American Heart Association and executive director of the Katz Institute for Women’s Health at Northwell Health in New York City.
She said: “Cardiovascular disease is the leading cause of death for women and remains their #1 health risk overall.
“While many people may think these conditions like high blood pressure are only occurring in older women, we know this is not the case.
“We know the factors that contribute to heart disease and stroke begin early in life, even among young women and girls.
“The impact is even greater among those experiencing adverse social determinants of health such as poverty, low literacy, rural residence and other psychosocial stressors.
“Identifying the types of trends outlined in this report is critical to making meaningful changes that can reverse this course.”
The statement noted that not all projections were negative.
Rates of high cholesterol are expected to decline among most groups of women, and improvements are anticipated in behaviours such as healthier eating, increased physical activity and reduced smoking.
Previous simulation studies identified potential ways to reverse current trends.
A 10 per cent reduction in risk factors including high blood pressure, high cholesterol, diabetes and obesity, combined with a 20 per cent improvement in controlling blood pressure, blood sugar and cholesterol, could reduce cardiovascular and stroke events, including deaths, by 17 to 23 per cent.
Cutting obesity by half and doubling risk factor control could reduce events and deaths by 30 to 40 per cent.
Maddox said: “Society has come so far in medical advancements, but the same can’t be said for innovation and progress around cardiovascular health, wellness and prevention.
“These projections emphasise how critical it is that we start focusing on how to help all people stay healthy.
“In this new era of digital health, artificial intelligence and new metabolic medication options, health care professionals increasingly have the tools to do this, but not yet the systems.”
Rosen added: “Every woman of every age should understand her risk of heart disease and stroke and be empowered to take action to reduce that risk.
“Know your numbers, listen to your body and be an advocate for your health. Additionally, support girls and women in your life to do the same.
“We can make a difference, we can be the difference.”
Opinion
The NHS doesn’t have a productivity problem: It has a precision problem

By Dr Melinda Rees, CEO, Psyomics
Spend enough time in the NHS and you stop flinching at the word “productivity”.
You hear it in every strategy document, every board meeting, every government announcement.
And almost every time, it means the same thing: do more with less.
It’s the wrong framing.
After 25 years working in and around clinical services – from NHS leadership to service delivery in the independent sector to where I am building technology that works with NHS mental health services – I’d argue it’s part of why progress has been so hard to achieve and sustain.
Productivity in healthcare shouldn’t mean squeezing more out of an already over stretched workforce.
It should mean something more precise: delivering greater value per pound by protecting and deploying finite clinical expertise intelligently.
That distinction sounds subtle. In practice, it changes everything about how you approach the problem.
The demand side of this equation isn’t going to get easier.
Multi-morbidity is rising. Mental health need is growing. Cases are more complex, and patient expectations – rightly – are higher.
The assumption that we can recruit our way out of this is understandable but wrong.
Training pipelines take years. Financial resources are finite. Even in an optimistic scenario, workforce expansion alone doesn’t close the gap.
So, the real question isn’t how do we get more clinicians. It’s whether we’re deploying the ones we have with maximum precision.
And honestly, in most services, the answer is no.
- Clinical time – the most valuable finite resource in the system – is routinely lost to things that have nothing to do with clinical decision-making.
- Administration.
- Repetitive documentation.
- Poor workflow.
- Systems that don’t share information across boundaries.
- Inconsistent and variable clinical decision-making.
- Referrals that shouldn’t have reached a specialist clinic in the first place.
- Reactive care models that wait for deterioration rather than anticipating it.
- Gathering baseline information that could have been collected earlier, more consistently, and without the clinician in the room.
Meanwhile, the waiting list grows.
This isn’t a motivation problem or a workforce culture problem. It’s a system design problem.
And it’s solvable – meaningfully – if we’re willing to rethink how technology fits into the picture.
The challenge with digital implementation in the NHS has rarely been the technology itself – it’s been layering new tools onto processes that were already under strain.
A new system that digitises an inefficient workflow is still an inefficient workflow.
Real productivity gains come when technology is used to redesign how work actually happens – not just record it.
In practice, that means four things.
First, automating the tasks that don’t require clinical expertise – structured data capture, digital triage, standardised assessment pathways.
Every minute saved on documentation is a minute returned to care. At scale, those minutes add up fast.
Second, bringing patients into the process earlier.
When a patient contributes structured, meaningful information before their first appointment, the clinician and patient have a great head start.
Better routing, smarter questions, faster and safer decisions, quicker access to the right treatment.
Third, monitoring caseloads intelligently.
Utilising tools that flag deterioration or signal when a care plan needs to change, rather than waiting for a crisis to trigger a review.
Finally fourth, making sure every appointment actually advances care. That sounds obvious.
In practice, without recorded structured outcome data, it’s surprisingly hard to know.
None of this requires drastic AI transformation or futuristic promises.
Some of the biggest gains come from making simple workflow tasks consistent and seamless – the kind of unglamorous operational improvement that doesn’t make headlines but compounds quietly across thousands of patient interactions and increases productivity.
A 1-2 per cent productivity gain per clinician sounds modest.
At NHS scale, across millions of appointments, it isn’t. It’s the difference between a system grinding and one with genuine headroom to breathe.
It’s the difference between your close relative being able to get an appointment when they genuinely need one or languishing on a waiting list with little hope.
I think about this a lot through the lens of mental health services specifically, where I’ve spent most of my career and where Psyomics works.
Mental health has historically been underfunded and under-prioritised – something that disproportionately affects women, both as patients and as the clinicians and carers holding those services together.
The pressure to do more with less lands hardest here. And the argument that productivity means working harder is, in this context, particularly damaging.
Burnout in mental health services isn’t a footnote. It’s a crisis within a crisis.
The better argument – the one I’d like to see shape NHS policy – is that productivity means precision.
Precision in how we route patients. Precision in how we use structured data to reduce variation and improve decisions. Precision in how we protect clinical time for the work that only a skilled clinician can do and loves to do.
That’s not a technology story, exactly. It’s a system design story, in which technology plays an enabling role.
The NHS doesn’t need to do more with less.
The goal isn’t harder-working, exhausted clinicians – it’s smarter-working, compassionate enabled clinicians, and patients who are seen sooner.
Insight
Women’s health leaders warn of censorship
Features
Study reveals how oestrogen protects women from high blood pressure

Oestrogen helps protect premenopausal women from hypertension by relaxing and widening blood vessels, according to new research examining why women develop high blood pressure less often before menopause.
High blood pressure, also known as hypertension, affects more than a billion people worldwide and is a leading cause of heart disease and stroke.
Premenopausal women are less likely to develop the condition than men or postmenopausal women, but the biological reason has been unclear.
Researchers used a mathematical model of the cardiovascular and kidney systems to analyse how oestrogen influences blood pressure.
The analysis found that oestrogen’s strongest protective effect comes from vasodilation, the process by which blood vessels relax and widen, helping blood flow more easily and lowering pressure in the arteries.
Anita Layton, Canada 150 Research Chair Laureate in Mathematical Biology and Medicine and professor of applied mathematics, said: “Oestrogen is often thought of only in terms of reproductive health, but it plays a much broader role in how the body functions.
“It affects how blood vessels respond, how the kidneys regulate fluids and how different systems communicate with one another.
“What we found is that its impact on blood vessels is especially important for regulating blood pressure.”
The findings may also have implications for treating women after menopause, when oestrogen levels naturally decline.
The model predicted that angiotensin receptor blockers, a common class of blood pressure drugs, could be more effective than another widely used treatment group known as angiotensin converting enzyme inhibitors in treating women with hypertension, even after oestrogen levels decline after menopause.
Layton said her team has spent years developing a mathematical model of women’s kidneys and the cardiovascular system, designed to explore how different biological mechanisms affect blood pressure.
The model allows researchers to test individual effects separately and examine how each influences the body.
“We can turn on one effect, then another, and see exactly how each one affects the body,” Layton said.
She added: “For too long, women’s health, especially older women’s health, has been overlooked by medicine.
“Understanding how age and sex affect the body and, therefore, treatment, is an equity issue.”
Entrepreneur4 weeks agoUS startup builds wearable hormone tracker
Fertility4 weeks agoFrance urges 29-year-olds to start families now
Mental health4 weeks agoWomen with ADHD almost twice as likely to experience perimenopause symptoms, study finds
Entrepreneur4 weeks agoKindbody unveils next-gen fertility platform
Menopause4 weeks agoMenopause specialist Haver joins Midi Health
Entrepreneur2 weeks agoOura launches women’s health AI model
Mental health4 weeks agoThe $128b paradox: Corporate wellness vs women’s burnout
Entrepreneur4 weeks agoKate Ryder headlines Women’s Health Week USA 2026 as full agenda goes live













